You are here

Bluebird Bio

Bluebird bio lays off staffers in Europe as Zynteglo rollout hits an early reimbursement snag

Bluebird bio lays off staffers in Europe as Zynteglo rollout hits an early reimbursement snag

Fierce Pharma

Flag link:

Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors

Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors

Fierce Biotech

Flag link:

New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds

New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds

BioPharma Dive

Bristol Myers Squibb

Multiple Myeloma

Flag link:

Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts

Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts

Fierce Pharma

Bristol Myers Squibb

Flag link:

FDA approves first CAR-T cell therapy for multiple myeloma

FDA approves first CAR-T cell therapy for multiple myeloma

BioPharma Dive

Bristol-Myers Squibb

Multiple Myeloma

Flag link:

Bluebird bio CMO quits amid a roller coaster year and upcoming split

Bluebird bio CMO quits amid a roller coaster year and upcoming split

Fierce Biotech

Flag link:

Blown off course, Bluebird shares tick up on positive gene therapy readout

Blown off course, Bluebird shares tick up on positive gene therapy readout

Fierce Biotech

Flag link:

EMA begins safety review of bluebird gene therapy following AML case in related therapy

EMA begins safety review of bluebird gene therapy following AML case in related therapy

Endpoints

Flag link:

Bluebird seeks gene therapy trial restart after cancer scare

Bluebird seeks gene therapy trial restart after cancer scare

Pharmaforum

sickle cell disease

Flag link:

Bluebird’s Zynteglo safety snag could spell trouble for other gene therapies: analysts

Bluebird’s Zynteglo safety snag could spell trouble for other gene therapies: analysts

Fierce Pharma

clinical trials

Flag link:

Bluebird stops studies of sickle cell gene therapy after new cancer cases

Bluebird stops studies of sickle cell gene therapy after new cancer cases

BioPharma Dive

sickle cell disease

clinical trials

Flag link:

JPM: Bluebird to spin off cancer therapies into new company

JPM: Bluebird to spin off cancer therapies into new company

Fierce Biotech

Flag link:

10 Biopharma Stories to Look Forward to in 2021

10 Biopharma Stories to Look Forward to in 2021

BioSpace

venture capital

TG Therapeutics

Flag link:

3 FDA Dates Biotech Investors Should Circle in 2021

3 FDA Dates Biotech Investors Should Circle in 2021

Motley Fool

Multiple Myeloma

Alzheimer's disease

targeted therapeutics

maringal zone lymphoma

Flag link:

Bluebird trumpets long-term data from beta-thalassaemia gene therapy

Bluebird trumpets long-term data from beta-thalassaemia gene therapy

Pharmaforum

beta-thalassemia

Flag link:

FDA gene therapy holdups suggest closer scrutiny by agency

FDA gene therapy holdups suggest closer scrutiny by agency

BioPharma Dive

Sarepta Therapeutics

Voyager Therapeutics

Flag link:

Can bluebird bio Recover From Another Major Setback?

Can bluebird bio Recover From Another Major Setback?

Motley Fool

sickle cell disease

Flag link:

FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay

FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay

Endpoints

sickle cell disease

Flag link:

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

Fierce Biotech

Bristol-Myers Squibb

priority review

Flag link:

Pages